Announcement • Jun 09
Totally plc Announces Director Resignations Totally plc confirmed that, further to its announcement the Board of Totally has now appointed Tim Vance and Sam Woodward as Joint Administrators of the Company, being the parent company of the Totally group of companies (the "Group"), following which each of the Company's directors, being Simon Stilwell, John McMullan, Robert Forsyth and Robert Harris resigned as directors of the Company. Following the appointment of the Joint Administrators over Totally Plc, the Company has completed the disposal of the Group's Elective Care and Corporate Wellbeing subsidiaries, and the business and assets of the Urgent Care division to PHL Group. This transaction sees the continued and uninterrupted provision of all services previously delivered by the Group. New Risk • May 25
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (33% average weekly change). Market cap is less than US$10m (UK£589.6k market cap, or US$798.1k). Minor Risk Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). New Risk • May 01
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: UK£2.75m (US$3.65m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (25% average weekly change). Market cap is less than US$10m (UK£2.75m market cap, or US$3.65m). Recent Insider Transactions • Mar 26
Joint MD of Pioneer Health Care recently bought UK£144k worth of stock On the 21st of March, John McMullan bought around 4m shares on-market at roughly UK£0.034 per share. This transaction increased John's direct individual holding by 1x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought UK£193k more in shares than they have sold in the last 12 months. Announcement • Feb 22
Totally plc Announces Chief Executive Officer Changes Totally plc announced that Wendy Lawrence has agreed with the Board that she will step down from her role as Chief Executive Officer with immediate effect. The Board intends to initiate a formal search process to identify a new Chief Executive Officer as soon as possible and will update the market in due course. Until such time as a new Chief Executive Officer is appointed, Professor Prasad Godbole, Totally's current Chief Operating Officer has been appointed interim Chief Executive Officer of the Company with immediate effect. Professor Prasad Godbole will report directly to Simon Stilwell, Chairman of the Company, but will not be appointed to the board at the present time. New Risk • Feb 21
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: UK£7.17m (US$9.07m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Market cap is less than US$10m (UK£7.17m market cap, or US$9.07m). Announcement • Feb 21
Totally plc Announces Wendy Lawrence Steps Down from the Board Totally plc announced that Wendy Lawrence has agreed with the Board that she will step down from her role and will leave the Board with immediate effect. Announcement • Feb 16
Totally plc Provides Earnings Guidance for the Fiscal Year Ending 31 March 2025 and 31 March 2026 Totally plc provided earnings guidance for the fiscal year ending 31 March 2025 and 31 March 2026. The company was not reliant on the extension of the NHS 111 Contract for the delivery of its 31 March 2025, forecast and therefore remains confident of delivering FY25 performance in line with expectations of £85 million revenue.
The Board's financial expectations for the year ending 31 March 2026 did assume a renewal of the NHS 111 Contract, however at a reduced level. Work will commence to redeploy workforce where possible along with securing new contracts with new providers, although exceptional costs are expected. Based on the current revenue run rate of the Company, new contract wins and the current new business pipeline the Board now expects the financial performance of FY26 to be at a similar level to that which is expected to be reported for FY25. Announcement • Jan 13
Totally plc Announces Appointment of Robert Harris to Board of Directors, Effective from 9 February 2025 Totally plc announced the appointment of Robert Harris to the Totally Board of Directors with effect from 9 February 2025. Robert will join the Board as a Non-Executive Director and Chair of the Remuneration Committee. Robert has an impressive track record in healthcare including responsibility for government health policy, strategy and hospital regulation. He has held multiple Executive and Non-Executive positions within successful healthcare organisations, both NHS and private, and was the first National Director of Strategy at NHS England from 2012 to 2014. He is currently a Non-Executive Director at DHU Healthcare CIC, a provider of NHS 111, out of hours and urgent care services, a role which he will step away from prior to taking up the position at Totally, and also a Non-Executive Director at Optegra Eye Health Care, a leading provider of eye surgery across several European countries. Previous roles within the NHS include Executive Director of Operations and Performance at NHS Midlands & East Strategic Health Authority and Executive Director of Commissioning & Performance at NHS East of England Strategic Health Authority. Robert was the first Policy Director of the UK hospital regulator, Monitor, and was also previously Non-Executive Chair of Medinet Clinical Services, the leading provider of insourced clinical services to the NHS. Following the above appointment and in line with best corporate governance practice, having spent nine years as a Non-Executive Director, Tony Bourne, Non-Executive Director has notified the Company that he will step off the Board with effect from 8 February 2025. Robert James Barrington Hugo Harris, age 63, is currently or has been a Director of the following companies within the past five years: Current Directorships: Optegra Eye Health Care, DHU Healthcare CIC, and Oxonar Ltd. Previous Directorships: Medinet Clinical Services, LHG GP Partnership, SP Care Holdings Limited, Norse Medica Limited, and Phoenix Care Topco Ltd. Reported Earnings • Nov 12
First half 2025 earnings released: EPS: UK£0 (vs UK£0.009 loss in 1H 2024) First half 2025 results: EPS: UK£0 (improved from UK£0.009 loss in 1H 2024). Revenue: UK£41.7m (down 25% from 1H 2024). Net income: UK£5.0k (up UK£1.87m from 1H 2024). Profit margin: 0% (up from net loss in 1H 2024). Revenue is forecast to grow 3.1% p.a. on average during the next 2 years, compared to a 7.2% growth forecast for the Healthcare industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 60 percentage points per year, which is a significant difference in performance. Announcement • Oct 18
Totally plc to Report Q2, 2025 Results on Nov 06, 2024 Totally plc announced that they will report Q2, 2025 results on Nov 06, 2024 Announcement • Sep 05
Totally plc, Annual General Meeting, Sep 27, 2024 Totally plc, Annual General Meeting, Sep 27, 2024. Location: the registered office of the company, cardinal square first floor west, 10 nottingham road, england de1 3qt, derby United Kingdom Announcement • Aug 02
Totally plc Appoints Laurence Goldberg to Its Board Totally plc announced appointment of Laurence Goldberg to its Board of Directors with immediate effect. Laurence joined Totally in 2022 as Director of Finance. He has a career in finance spanning more than 35 years, with ten years at Director level. Most recently, Laurence has held Finance Director roles in Private equity and energy start-ups, including WM5G, and Tonik Energy, building upon previous roles at EON, Virgin Media and Lloyds Bank where he qualified as an accountant. He also volunteers as the Treasurer & Member of the Trustee Board for the Institute of Money Advisers. Laurence James Goldberg, age 59, is currently or has been a Director of the following companies within the past five years: Current Directorships: INSTITUTE OF MONEY ADVISERS and LAUREL ACCOUNTANCY LTD. Previous Directorships: BEDROCK COMMERCIAL LTD and BEDROCK CO-LIVING LTD. Board Change • Jul 31
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Chairman Simon Stilwell was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Jul 25
Full year 2024 earnings released: UK£0.016 loss per share (vs UK£0.009 profit in FY 2023) Full year 2024 results: UK£0.016 loss per share (down from UK£0.009 profit in FY 2023). Revenue: UK£106.7m (down 21% from FY 2023). Net loss: UK£3.13m (down 276% from profit in FY 2023). Revenue is expected to decline by 6.1% p.a. on average during the next 2 years, while revenues in the Healthcare industry in the United Kingdom are expected to grow by 7.6%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 38 percentage points per year, which is a significant difference in performance. Announcement • Jul 24
Totally plc Announces Changes to its Board Totally plc announced the appointment of Bob Forsyth to the Totally Board of Directors with effect from 25 July2024. Bob Forsyth will join the Board as a Non-Executive Director, Chair of the Audit Committee and member of the Remuneration and Nominations Committees. Bob is currently the Chair of London's Air Ambulance. Prior to this he was the Audit & Risk Chair of London's Air Ambulance and has been the Audit & Risk Chair for Ernst & Young's (‘EY’) pension scheme since 2022. Until June 2023, he was a listed audit partner with EY advising on the governance of FTSE250, small cap and AIM-listed businesses and also led transformational change programmes, including cultural change and delivering improved performance. As an audit partner he advised many listed businesses on governance and capital market transactions. Following the above appointment and in line with best corporate governance practice, having spent nine years as a Non-Executive Director, MikeRogers, Non-Executive Director has notified the Company that he will step off the Board with effect from 24 July 2024. Announcement • Jul 18
Totally plc to Report Fiscal Year 2024 Results on Jul 24, 2024 Totally plc announced that they will report fiscal year 2024 results at 8:00 AM, GMT Standard Time on Jul 24, 2024 New Risk • Apr 05
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: UK£7.86m (US$9.93m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Market cap is less than US$10m (UK£7.86m market cap, or US$9.93m). Announcement • Feb 02
Totally plc Announces Resignation Lisa Barter as Chief Financial Officer Totally plc announces that Chief Financial Officer, Lisa Barter, has decided to step down from her role with effect from 1st February 2024. Board Change • Dec 06
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Director Mike Rogers was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Recent Insider Transactions • Dec 05
Insider recently bought UK£61k worth of stock On the 29th of November, Simon Stilwell bought around 1m shares on-market at roughly UK£0.061 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought UK£108k more in shares than they have sold in the last 12 months. Reported Earnings • Nov 30
First half 2024 earnings released: UK£0.009 loss per share (vs UK£0.005 profit in 1H 2023) First half 2024 results: UK£0.009 loss per share (down from UK£0.005 profit in 1H 2023). Revenue: UK£55.8m (down 21% from 1H 2023). Net loss: UK£1.87m (down 310% from profit in 1H 2023). Revenue is forecast to grow 8.5% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Healthcare industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings. Buying Opportunity • Nov 29
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 46%. The fair value is estimated to be UK£0.073, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.7% over the last 3 years. Meanwhile, the company became loss making. New Risk • Nov 28
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risks Paying a dividend despite having no free cash flows. Large one-off items impacting financial results. Shareholders have been diluted in the past year (4.9% increase in shares outstanding). Market cap is less than US$100m (UK£12.5m market cap, or US$15.9m). Announcement • Nov 22
Totally plc to Report First Half, 2024 Results on Nov 28, 2023 Totally plc announced that they will report first half, 2024 results on Nov 28, 2023 Buying Opportunity • Oct 23
Now 23% undervalued after recent price drop Over the last 90 days, the stock is down 50%. The fair value is estimated to be UK£0.081, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 9.2% over the last 3 years. Meanwhile, the company has become profitable. Buying Opportunity • Sep 27
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 62%. The fair value is estimated to be UK£0.081, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 9.2% over the last 3 years. Meanwhile, the company has become profitable. Reported Earnings • Aug 14
Full year 2023 earnings released: EPS: UK£0.009 (vs UK£0.006 in FY 2022) Full year 2023 results: EPS: UK£0.009 (up from UK£0.006 in FY 2022). Revenue: UK£135.7m (up 6.5% from FY 2022). Net income: UK£1.78m (up 65% from FY 2022). Profit margin: 1.3% (up from 0.8% in FY 2022). Revenue is forecast to grow 2.3% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Healthcare industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 107% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. New Risk • Jul 11
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 22% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Payout ratio: 107% Paying a dividend despite having no free cash flows. High level of non-cash earnings (22% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Shareholders have been diluted in the past year (4.9% increase in shares outstanding). Market cap is less than US$100m (UK£25.0m market cap, or US$32.3m). Reported Earnings • Jul 10
Full year 2023 earnings released: EPS: UK£0.009 (vs UK£0.006 in FY 2022) Full year 2023 results: EPS: UK£0.009 (up from UK£0.006 in FY 2022). Revenue: UK£135.7m (up 6.5% from FY 2022). Net income: UK£1.78m (up 65% from FY 2022). Profit margin: 1.3% (up from 0.8% in FY 2022). Revenue is expected to decline by 2.2% p.a. on average during the next 2 years, while revenues in the Healthcare industry in the United Kingdom are expected to grow by 5.8%. Over the last 3 years on average, earnings per share has increased by 107% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Announcement • Jul 07
Totally plc to Report Fiscal Year 2023 Results on Jul 10, 2023 Totally plc announced that they will report fiscal year 2023 results on Jul 10, 2023 Buying Opportunity • Mar 02
Now 42% undervalued after recent price drop Over the last 90 days, the stock is down 41%. The fair value is estimated to be UK£0.34, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Meanwhile, the company has become profitable. Announcement • Jan 24
Totally plc Declares Interim Dividend, Payable on 24 February 2023 Totally plc declared an interim dividend of 0.5 pence per ordinary share. This interim dividend will be paid on 24 February 2023 to shareholders on the register as at 3 February 2023. The shares have an ex-dividend date of 2 February 2023. Price Target Changed • Nov 16
Price target increased to UK£0.72 Up from UK£0.63, the current price target is an average from 2 analysts. New target price is 123% above last closing price of UK£0.33. Stock is down 9.1% over the past year. The company is forecast to post earnings per share of UK£0.019 for next year compared to UK£0.0059 last year. Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 1 highly experienced director. Clinical Quality Director & Director Gloria Cooke was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Jul 13
Full year 2022 earnings released: EPS: UK£0.006 (vs UK£0.002 in FY 2021) Full year 2022 results: EPS: UK£0.006 (up from UK£0.002 in FY 2021). Revenue: UK£127.4m (up 12% from FY 2021). Net income: UK£1.08m (up 240% from FY 2021). Profit margin: 0.8% (up from 0.3% in FY 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 10%, compared to a 33% growth forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 114% per year but the company’s share price has only increased by 60% per year, which means it is significantly lagging earnings growth. Price Target Changed • Apr 27
Price target increased to UK£0.72 Up from UK£0.63, the current price target is an average from 2 analysts. New target price is 55% above last closing price of UK£0.47. Stock is up 19% over the past year. The company is forecast to post earnings per share of UK£0.0057 for next year compared to UK£0.0017 last year. Board Change • Apr 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 1 highly experienced director. Clinical Quality Director & Director Gloria Cooke was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 17
First half 2022 earnings released: EPS UK£0.006 (vs UK£0.002 in 1H 2021) The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2022 results: Revenue: UK£61.6m (up 14% from 1H 2021). Net income: UK£1.14m (up 280% from 1H 2021). Profit margin: 1.8% (up from 0.6% in 1H 2021). Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has increased by 30% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Jul 07
Full year 2021 earnings released: EPS UK£0.002 (vs UK£0.018 loss in FY 2020) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: UK£113.7m (up 7.3% from FY 2020). Net income: UK£318.0k (up UK£3.15m from FY 2020). Profit margin: 0.3% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has increased by 17% per year, which means it is well ahead of earnings. Is New 90 Day High Low • Jan 21
New 90-day high: UK£0.29 The company is up 54% from its price of UK£0.19 on 23 October 2020. The British market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is up 8.0% over the same period. Is New 90 Day High Low • Jan 04
New 90-day high: UK£0.23 The company is up 29% from its price of UK£0.17 on 06 October 2020. The British market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is up 9.0% over the same period. Is New 90 Day High Low • Dec 04
New 90-day high: UK£0.22 The company is up 10.0% from its price of UK£0.20 on 04 September 2020. The British market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is up 14% over the same period. 
